OpenAI is exploring a "value sharing" business model to acquire financial stakes in discoveries made by its corporate customers. CFO Sarah Friar revealed the strategy during a panel in Davos. The company intends to move beyond standard usage fees to capture a portion of the financial upside its AI technology helps create.
Friar cited drug discovery as an example where OpenAI could secure a license to a drug developed on its platform. This strategy targets large-scale enterprise partnerships in R&D-intensive fields. The model is not intended for individual users.
The move aims to align OpenAI’s financial success with customer breakthroughs. These new revenue streams would help the company offset its high infrastructure costs.